A phase 1 dose escalation study of ARQ 197 in adult patients with metastatic solid tumors.

Trial Profile

A phase 1 dose escalation study of ARQ 197 in adult patients with metastatic solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2009

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 01 Jun 2009 A total of 74 patients have been treated in this trial and final results were presented at ASCO, according to an ArQule media release.
    • 01 Jun 2009 Status changed from recruiting to completed. Final results were presented at ASCO.
    • 26 May 2009 Additional lead trial investigator (Makhail T) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top